{
    "clinical_study": {
        "@rank": "156445", 
        "acronym": "ROSAM", 
        "arm_group": [
            {
                "arm_group_label": "SAMITAL\u00ae sachets, oral suspension", 
                "arm_group_type": "Experimental", 
                "description": "SAMITAL\u00ae sachets for oral suspension, 20 mL, four times a day."
            }, 
            {
                "arm_group_label": "Placebo sachets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo sachets for oral suspension, 20 mL, four times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to:\n\n        -  evaluate the activity of SAMITAL in reducing the incidence of severe mucositis in\n           head-and-neck cancer patients undergoing chemo-radiotherapy.\n\n        -  assess tolerability of SAMITAL and the impact on patients reported outcomes."
        }, 
        "brief_title": "Role of SAMITAL\u00ae in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Head-and-neck Squamous Cell Carcinoma", 
            "Oral Mucositis."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms", 
                "Stomatitis", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven squamous cell carcinomas of the head-and-neck\n\n          -  Eligible primary tumor sites: oral cavity, oropharynx, larynx, hypopharynx\n\n          -  Stage III or IV disease without evidence of distant metastases\n\n          -  Patients candidate to definitive concurrent chemo-radiotherapy or induction\n             chemotherapy followed by chemo-radiotherapy\n\n          -  Age \u2265 18 years\n\n          -  Karnofsky Performance Status \u226570\n\n          -  Life expectancy \u22656 months\n\n          -  Able to swallow and retain oral medication\n\n          -  Good state of dentition\n\n          -  Patients must be available for treatment and follow-up\n\n          -  Confirmation of adequate contraception use by the patient and/or partner\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Previous radiotherapy of the oral cavity, and/or oropharynx, larynx, hypopharynx\n\n          -  Serious co-morbidities: uncontrolled heart disease, heart failure within 6 months\n             prior to study participation, history of serious neurological and/or psychiatric\n             abnormalities.\n\n          -  Chronic administration of steroids or immunosuppressants\n\n          -  Pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941992", 
            "org_study_id": "IOV-HN-1-2012 ROSAM", 
            "secondary_id": "2012-002046-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "SAMITAL\u00ae sachets, oral suspension", 
                "intervention_name": "SAMITAL\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo sachets", 
                "intervention_name": "Placebo sachets", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "head and neck", 
            "Squamous Cell Carcinoma", 
            "oral mucositis", 
            "Chemo-radiotherapy"
        ], 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "zip": "35100"
                }, 
                "name": "Radiotherapy Department, Istituto Oncologico Veneto"
            }, 
            "investigator": {
                "last_name": "Guido Sotti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of SAMITAL\u00ae in Prevention and Treatment of Oral Mucositis in Patients Treated With Chemo-radiation (CT/RT)for Head-and-neck Squamous Cell Carcinomas. A Double-blind, Phase 2 Placebo Controlled, Randomized Trial.", 
        "other_outcome": {
            "measure": "Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35)", 
            "safety_issue": "No", 
            "time_frame": "Within 19 weeks after starting Radiotherapy"
        }, 
        "overall_contact": {
            "email": "gianluca.desalvo@ioveneto.it", 
            "last_name": "Gian Luca De Salvo, MD", 
            "phone": "0039 0498215710"
        }, 
        "overall_official": {
            "affiliation": "Radiotherapy Department, Istituto Oncologico Veneto", 
            "last_name": "Guido Sotti, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Italy: Ministry of Health", 
                "Italy: National Institute of Health", 
                "Italy: The Italian Medicines Agency"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.", 
            "safety_issue": "Yes", 
            "time_frame": "Within 19 weeks after starting Radiotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941992"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0)", 
            "safety_issue": "Yes", 
            "time_frame": "Within 19 weeks after starting Radiotherapy"
        }, 
        "source": "Istituto Oncologico Veneto IRCCS", 
        "sponsors": {
            "collaborator": {
                "agency": "Indena S.p.A", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Istituto Oncologico Veneto IRCCS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}